Menu
Recruiting NCT07069452

Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke

Observational Stroke, Ischemic Thrombectomy Thrombolytic Therapy Brain Ischemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Stroke, Ischemic, Thrombectomy, Thrombolytic Therapy, Brain Ischemia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

TARGET-ASPECT (Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke)

Overview

This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.

Primary outcome measures

  • Favorable functional outcome defined as a mRS score of 0 to 2 at 90 days [Time frame: 90 days]

Eligibility criteria

Inclusion criteria

  • Patients aged 18 years or older
  • Confirmed acute ischemic stroke on imaging
  • Treated with both thrombolysis and thrombectomy
  • Clinical follow-up data available at 90 days (mRS score)

Exclusion criteria

  • Primary hemorrhagic stroke
  • Early death or loss to follow-up without evaluation
  • Poor-quality imaging that cannot be analyzed

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Centre Hospitalier de Gonesse — Gonesse

Identifiers

NCT: NCT07069452 · 0111_NEUROLOGIE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗